Difference between revisions of "TF Actinium"

From New IAC Wiki
Jump to navigation Jump to search
Line 12: Line 12:
  
 
https://phys.org/news/2018-06-scientists-actinium-rare-medical-radioisotope.html
 
https://phys.org/news/2018-06-scientists-actinium-rare-medical-radioisotope.html
 +
 +
DOE IP is focused on Ac-225, but its production via limited to the amount of  Th-229 on hand (so called Thorium cow).  So we are also pursuing accelerator based production (mostly proton machines, but also some photo-nuclear reactions).  The proton machines also generates comparable amount of  Ac-227 which is problematic due to its long lifetime.
  
 
==Ac-226==
 
==Ac-226==

Revision as of 04:28, 22 July 2020

TF_Isotopes


Current production facilities

Ac-225

An alpha emitter for Cancer Therapy

made at : BNL (BLIP), LANL (IPF), ORNL


https://phys.org/news/2018-06-scientists-actinium-rare-medical-radioisotope.html

DOE IP is focused on Ac-225, but its production via limited to the amount of Th-229 on hand (so called Thorium cow). So we are also pursuing accelerator based production (mostly proton machines, but also some photo-nuclear reactions). The proton machines also generates comparable amount of Ac-227 which is problematic due to its long lifetime.

Ac-226

Single neutron knockout of Ra-226 goes to Ra-225 which decays to Ac-226 after 14 days. Ac-226 is a beta emitter with a half life of 29 hours.

Ac-227 (Cancer Therapy)

ORNL (HFIR)

Ac-227 is presently produced by the DOE IP to be incorporated into the Bayer Xofigo drug, where the mode of interest is that Ac-227 -> Ra-226 which eventually emits an alpha (Ra-226 generators). so the beta emission is not what drives its use as a cancer therapy, the resulting alpha from the Ra-226 is what makes it useful.


TF_Isotopes